ClinicalTrials.gg
Status unknownNCT03852849Updated Feb 25, 2019

Rapid Build of HIV Related Protective Barriers

An interventional study of Personal involved intervention strategies and The dosage of 400mg EFV in Viral Suppression of HIV Infection, sponsored by National Center for AIDS/STD Control and Prevention, China CDC. Status unknown at 2 sites in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-25.

Sponsored by National Center for AIDS/STD Control and Prevention, China CDC · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Feb 2019), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in HIV Infections with a site in China — 10 open to participants now, 10 under way, none of them phase 3. HIV Infections · China.

Planned enrollment
11th of 50
600 · median 145
Started
2019
with 2 others
No phase
16 of 67
2 open now
Registered
38th of 67
by date
Lead sponsor
4 of 67
National Center for AIDS/STD Control and Prevention, China CDC

Among the 67 studies in HIV Infections with a site in China, this one is the 11th largest by planned enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2019, is one of 16 with no phase, and was the 38th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

10 of the 67 studies in HIV Infections with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in HIV Infections with a site in China, or all of them as a file.
02

Study summary

The purpose of the study is to screen the optimal intervention strategies to rapid establish the protective barriers against HIV-infection by maximally decreasing the viremia among HIV- infected patients.

Read the detailed description

Sexual transmission became the primary route of HIV transmission in China and heterosexual transmission also contributed greatly to HIV epidemic which was mostly reported in South-west rural areas. In past years, Yunnan has experienced powerful campaign of scaling-up the HIV identification as well as antrertroviral therapy.

This study will investigate how to reach the last two of HIV'90-90-90 targets': to provide antiretroviral therapy (ART) for 90% of who diagnosed HIV infection and to achieve viral suppression for 90% of those treated.

The study population consists of participants who received an newly diagnosed HIV infection within the study period. All rerolled participants will be randomized into different study group. In intervention group, medical institutions will provide patients personal involved intervention strategies which guided by frequent viral load detection, and providing of the dosage form of 400 mg EFV in their antiviral therapy.

Main assessment measures are viral suppression rate of HIV-infected patients and treatment coverage .

03

Conditions studied

  • Viral Suppression of HIV Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -positive participants who received an newly diagnosed HIV infection within the study period
  • Having a current residential address inside of pilot site limits
  • Eighteen years old or above
  • HIV transmission is heterosexual contact

Exclusion criteria

Exclusion Criteria:

  • IDU
  • Having severe mental disorder
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
600 participants (estimated)

Study arms

  • No intervention
    routine care group

    Medical institutions will provide patients routine care according to the national program standard.

  • Experimental
    medicine intervention group

    The dosage of 400 mg EFV will be used in the antiviral therapy.

    Drug: The dosage of 400mg EFV

  • Experimental
    consolidated intervention group

    Medical institutions will provide personal involved intervention strategies as well as the providing of dosage form of 400 mgEFV in their antiviral therapy.

    Behavioral: Personal involved intervention strategies · Drug: The dosage of 400mg EFV

Interventions

  • BehavioralPersonal involved intervention strategies

    Medical institutions will provide personal involved intervention strategies for patients which guided by viral load testing monthly until viral load drop below the detection limit.

  • DrugThe dosage of 400mg EFV

    The dosage of 400mg EFV will be used in the antiviral therapy.

06

What researchers measure

Primary outcomes

  1. Viral suppression of HIV-infected patients

    Time frame: 12 months

Secondary outcomes

  1. Treatment coverage

    Time frame: 12 months

07

Study locations

2 sites
  • Lincang Center for Disease Control and Prevention
    Lincang, Yunnan, China
  • Wenshan Center for Disease Control and Prevention
    Wenshan, Yunnan, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2019; primary completion for Dec 2020, 21 months later.

Of 393 non-industry interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's planned 21 months is below that.

Counting every sponsor, half of 402 studies reached it within 28 months; a quarter within 16 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2019
First posted
Feb 25, 2019
StartEst.
Mar 1, 2019
Primary completionEst.
Dec 31, 2020
CompletionEst.
Mar 1, 2021
Last update
Feb 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03852849
Lead sponsor
National Center for AIDS/STD Control and Prevention, China CDC
Collaborators
Yunnan Center for Disease Control and Prevention, Yunnan AIDS Care Center
Responsible party
Sponsor
First posted
Feb 25, 2019
Start date
Mar 1, 2019 (estimated)
Primary completion
Dec 31, 2020 (estimated)
Completion
Mar 1, 2021 (estimated)
Last update
Feb 25, 2019

Study contacts

Zhao Yan, PHD
Contact
zhaoyan@chinaaids.cn
+86-10-5338-0980
Zhao Yan, PHD
principal investigator · National Center for AIDS/STD Control and Prevention

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion